Dianthus price target raised to $100 from $92 at Guggenheim

Guggenheim analyst Yatin Suneja raised the firm’s price target on Dianthus (DNTH) to $100 from $92 and keeps a Buy rating on the shares after the company announced tdata from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart in adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The data indicate a potential “best-in-class” profile, the analyst tells investors in a research note. Guggenheim believes the readout also de-risks claseprubart in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.